This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg
Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by
TEVA Pharmaceuticals USA with that of PLETAL Tablets manufactured by Otsuka Pharmaceuticals
Co., Ltd. for Otsuka America Pharmaceutical, Inc. following a single oral dose (1 x 50 mg
tablet) in healthy adult subjects administered under fasting conditions.